Prospective Data Registry and Quality of Life Assessment of Patients Undergoing Radiotherapy With the RefleXion Medical Radiotherapy System
Launched by REFLEXION MEDICAL · May 31, 2022
Trial Information
Current as of July 10, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying how well a new radiotherapy system, called the RefleXion Medical Radiotherapy System, works for patients with various types of cancer. The researchers want to learn about the effectiveness of different radiotherapy techniques used with this system, including intensity-modulated radiotherapy (IMRT), stereotactic body radiotherapy (SBRT), and a special method called biology-guided radiotherapy (BgRT). They will also examine how these treatments affect patients' quality of life, any side effects they may experience, and the costs associated with their care.
Eligible participants for the study are adults diagnosed with certain types of advanced or metastatic cancers who need radiotherapy. They must be able to understand and sign a consent form, and be willing to take precautions to avoid pregnancy during treatment. Throughout the trial, participants will receive the radiotherapy treatment and will be monitored for any side effects and improvements in their health. This study is actively recruiting patients and aims to gather important information to help improve cancer treatment in the future.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Able to comprehend and be willing to sign an informed consent form (ICF).
- • Diagnosis of local, loco-regionally advanced, or metastatic malignancy for whom radiotherapy is indicated
- • Radiotherapy to be delivered on the RMRS X1 with IMRT, SBRT, or BgRT technique.
- • Absence of concurrent illness that deems radiotherapy a contraindication which will be determined by the treating radiation oncologist.
- • Female and male patients of child-bearing potential willing to take appropriate precautions to avoid pregnancy while being treated. Permitted methods in preventing pregnancy should be communicated to the patient and their understanding confirmed by the treating Physician.
- • For BgRT patients only: Deemed eligible for BgRT with FDG per BgRT planning session
- Exclusion Criteria:
- • Pregnant or expecting to conceive during the study.
- • Has a known psychiatric or substance abuse disorder that would interfere with the participant's ability to cooperate with study requirements and follow-up visits.
- • Inability to maintain immobilization, supine position for planning and treatments.
- • For BgRT patients only: Known allergy to FDG
About Reflexion Medical
Reflexion Medical is an innovative healthcare company focused on advancing cancer treatment through the development of cutting-edge technologies in radiation therapy. With a commitment to enhancing patient outcomes, Reflexion Medical specializes in the design and implementation of therapeutic solutions that leverage real-time imaging and advanced treatment delivery systems. The company's clinical trials aim to evaluate the efficacy and safety of its proprietary systems, fostering collaboration with leading medical institutions to ensure rigorous scientific validation. Through its pioneering efforts, Reflexion Medical strives to transform the landscape of oncology care, ultimately improving the quality of life for patients battling cancer.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Pittsburgh, Pennsylvania, United States
Duarte, California, United States
Palo Alto, California, United States
Dallas, Texas, United States
New Haven, Connecticut, United States
Patients applied
Trial Officials
Sean Shirvani, MD
Study Director
RefleXion Medical
Karine Feghali, MD
Study Director
RefleXion Medical
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials